Solid IO

Solid IO develops a tumor-on-chip platform that replicates a patient’s specific tumor microenvironment and immune interactions to predict responses to immuno-oncology treatments. The technology provides real-time insights for clinicians to select personalized therapies and assists pharmaceutical companies in accelerating drug development through early biomarker validation and patient stratification. The platform is currently available for research use by biotech firms, pharmaceutical innovators, and cancer clinics.